Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P41181 (
collecting duct
)
5,183
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prostaglandins mediate autacrine and paracrine signaling over short distances. We used the renal
collecting duct
as a model system to test the hypothesis that local control of prostaglandin signaling is achieved by expressing inactivation in the same cell as synthesis. Immunocytochemical studies demonstrated that renal collecting ducts in situ express the prostaglandin (PG) synthesis enzyme, cyclooxygenase-1 (COX-1), as well as both components of prostaglandin metabolic inactivation, i.e. the prostaglandin uptake carrier prostaglandin transporter (PGT) and the enzyme
15-hydroxyprostaglandin dehydrogenase
. We characterized this system further using the
collecting duct
cell line Madin-Darby canine kidney (MDCK), which retains COX-2 and prostaglandin dehydrogenase expression but which has lost PGT expression. When we reintroduced PGT, it was correctly sorted to the apical membrane where it altered the sidedness of prostaglandin E2 (PGE2) release, a process we call "vectorial release via sided reuptake." Importantly, although COX-2 and prostaglandin dehydrogenase are expressed in the same MDCK cell, they must be compartmentalized because even in the presence of excess dehydrogenase newly synthesized PGE2 is released largely un-oxidized. However, when PGE2 undergoes first release and then PGT-mediated reuptake, significant oxidation takes place, suggesting that PGT imports PGE2 into the prostaglandin dehydrogenase compartment. Our data are consistent with a new model that offers significant new mechanisms for the fine control of eicosanoid signaling.
...
PMID:Prostaglandin signaling in the renal collecting duct: release, reuptake, and oxidation in the same cell. 1585 65
Tissue prostaglandin levels are determined by both biosynthesis and catabolism. The current studies report the expression and localization of
15-hydroxyprostaglandin dehydrogenase
(
15-PGDH
), a key enzyme in prostaglandin catabolism in the kidneys. We also investigated potential interactions between
15-PGDH
and cyclooxygenase (COX), a key enzyme in prostaglandin biosynthesis. Both
15-PGDH
mRNA and protein levels were significantly higher in kidney cortex than in papilla, which is opposite to the expression pattern of COX-2. In situ hybridization indicated that
15-PGDH
mRNA was mainly localized to the tubular epithelial cells in kidney cortex and outer medulla but not in the glomerulus or papilla. Dual immunofluorescent staining indicated that
15-PGDH
was expressed in the proximal tubule, cortical, and outer medullary thick ascending limb and
collecting duct
but not in the macula densa or papilla.
15-PGDH
levels were significantly lower in a macula densa cell line (MMDD1) than in a proximal tubule cell line. Although a high-salt diet decreased COX-2 expression in macula densa, it increased macula densa
15-PGDH
expression in both mouse and rat kidneys. In MMDD1 cells, a COX-2 inhibitor increased
15-PGDH
, whereas a COX-1 inhibitor had no effect. Furthermore, intense
15-PGDH
immunofluorescent staining was found in both macula densa and glomerulus in COX-2 knockout mice. The intrarenal distribution of
15-PGDH
and its interactions with COX-2 suggest that differential regulation of COX-2 and
15-PGDH
may play an important role in determining levels of prostaglandins involved in regulation of salt, volume, and blood pressure homeostasis.
...
PMID:Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase. 1805 86